

Andrew Hack

Partner, Bain Capital Life Sciences

Andrew A. F. Hack, M.D., Ph.D., is a Partner at Bain Capital Life Sciences which manages a series of private equity funds focused on investing in companies developing and commercializing transformative medicines, medical devices, diagnostics, and life sciences tools and services. Previously, he was chief financial officer of Editas Medicine, the first publicly-listed CRISPR gene editing company. Prior to that, he served as a portfolio manager at Millennium Management where he ran a healthcare hedge fund focused on investing in biotechnology, pharmaceutical, and life sciences companies. Earlier in his investment career, he was a securities analyst at a number of healthcare-focused hedge funds and investment banks in New York. He began his career in the biotechnology industry as Director of Life Sciences at Reify Corporation, a machine vision and machine learning-based drug discovery and technology company. Andrew currently serves as a member of the boards of directors of Alkeus Pharmaceuticals, Imperative Care, JenaValve Technology, and Swixx BioPharma. He has previously served on more than a dozen boards of directors, including Affinivax (acquired by GSK), Dynavax Technologies Corporation (NASDAQ: DVAX; acquired by Sanofi), Merida Biosciences, Mersana Therapeutics (NASDAQ: MRSN; acquired by Day One Biopharmaceuticals), and Nuvalent (NASDAQ: NUVL; acquired by GSK). Andrew received an A.B. in biology with special honors, an M.D., and a Ph.D. in molecular genetics and cell biology from the University of Chicago.